Surveying The Outcomes Of Lubiprostone (The STOOL Study) in Nursing Home Residents

This study has been withdrawn prior to enrollment.
(Enrollment was never begun.)
Sponsor:
Information provided by:
Synergy Health Solutions
ClinicalTrials.gov Identifier:
NCT00985569
First received: September 24, 2009
Last updated: November 22, 2010
Last verified: November 2010

September 24, 2009
November 22, 2010
November 2009
April 2010   (final data collection date for primary outcome measure)
To determine the overall reduction in the number of oral medicines taken by each NH resident at enrollment and at 60 days. [ Time Frame: 60 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00985569 on ClinicalTrials.gov Archive Site
  • Reduce the number of oral medicines being taken by any nursing home resident from 9 or more to fewer than 9. (Quality Indicator Number 6) [ Time Frame: 60 days ] [ Designated as safety issue: No ]
  • To compare the occurrence of fecal impaction during a 60-day period prior to initiating Lubiprostone with a 60 day period after initiating Lubiprostone. (Quality Indicator Number 11) [ Time Frame: 60 days ] [ Designated as safety issue: No ]
  • To compare the occurrence of fecal incontinence during a 60-day period prior to initiating Lubiprostone with a 60 day period after initiating Lubiprostone. [ Time Frame: 60 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Surveying The Outcomes Of Lubiprostone (The STOOL Study) in Nursing Home Residents
Surveying The Outcomes Of Lubiprostone (The STOOL Study): The Effect of Lubiprostone on Reducing the Number of Medications Prescribed to Nursing Home Residents and Its Impact on Selected Quality Indicators

The purpose is to assess the efficacy, clinical outcomes, and potential Quality Indicator benefits associated with the use of Lubiprostone in nursing home residents with a confirmed diagnosis of chronic idiopathic constipation.

The study is a prospective, observational, open-label, non-placebo, controlled study to measure the effects of Lubiprostone on CIC in nursing home residents. All clinical sites will follow a common protocol using standardizes definitions in which eligible patients will be asked to participate in the proposed study. During the course of the study, various selected parameters will be measured and compared to establish the clinical efficacy of Lubiprostone in the treatment of CIC.

The study sample (N=105) will be comprised of nursing home residents with a confirmed diagnosis of CIC. A power analysis generated a sample size of 97 residents. To protect the validity of the test, 8 residents were added to the final study sample to allow for losses to followup. Therefore, a final sample size of 105 residents was identified for the study.

Patients meeting the inclusion criteria will be recruited for participation in the study. 3 sites in Central Florida with multiple Nursing Homes per site will be recruited to participate in the proposed study.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Nursing Home Residents (adult subjects living in Nursing Homes)

Constipation
Not Provided
Lubiprostone
Subjects switching from current bowel medicines to lubiprostone
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
105
November 2010
April 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

Patients must meet all of the following criteria to be eligible for the study:

  • Adult men and women nursing home residents;
  • Confirmed diagnosis of CIC using Rome criteria;
  • Prescribed two or more laxatives, at recruitment;
  • Taking 9 or more oral medicines (including prescription, OTC and prn)
  • Free from conditions likely to be fatal within six months;
  • Able to read or understand English; and
  • Able and willing to provide informed consent or has a guardian/agent who can provide consent.

Exclusion Criteria:

  • Currently pregnant;
  • Presence of megacolon;
  • Presence of rectal sigmoid cancer;
  • Presence of colon cancer;
  • Presence of anal incompetence;
  • Conditions likely to be fatal within six months;
  • Taking 8 or fewer medicines;
  • Enrolled in hospice;
  • Non-English speaking patients; and
  • Unwilling or unable to provide informed consent and has no guardian/agent.
  • Expected to be discharged within 3 months.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00985569
STOOL
Yes
Malcolm Fraser, MD, CMD, Synergy Health Solutions
Synergy Health Solutions
Not Provided
Principal Investigator: Malcolm R Fraser, MD Synergy Health Solutions
Synergy Health Solutions
November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP